Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) EBITDA: 2022-2024

Historic EBITDA for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to -$3.3 million.

  • Addex Therapeutics' EBITDA fell 115.79% to -$2.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$6.1 million, marking a year-over-year decrease of 137.35%. This contributed to the annual value of -$3.3 million for FY2024, which is 2837.17% down from last year.
  • Per Addex Therapeutics' latest filing, its EBITDA stood at -$3.3 million for FY2024, which was down 2,837.17% from -$113,686 recorded in FY2023.
  • In the past 5 years, Addex Therapeutics' EBITDA ranged from a high of -$113,686 in FY2023 and a low of -$11.4 million during FY2022.
  • Moreover, its 3-year median value for EBITDA was -$3.3 million (2024), whereas its average is -$4.9 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 99.00% in 2023, then crashed by 2,837.17% in 2024.
  • Over the past 3 years, Addex Therapeutics' EBITDA (Yearly) stood at -$11.4 million in 2022, then spiked by 99.00% to -$113,686 in 2023, then slumped by 2,837.17% to -$3.3 million in 2024.